Selexipag as a Therapeutic Alternative for Treprostinil‐Induced Thrombocytopenia in Pulmonary Arterial Hypertension: A Case Report

Parenteral prostacyclin pathway agent-induced thrombocytopenia may require dose reduction or therapy discontinuation to mitigate the adverse events. However, the pulmonary arterial hypertension (PAH) guidelines do not suggest any strategy to overcome treprostinil-induced thrombocytopenia. Selexipag is an oral, non-prostanoid, selective IP receptor agonist. This is the first case report proposing the use of selexipag, due to its minimal thrombocytopenia risk, when severe treprostinil-induced thrombocytopenia occurs in practice. A 66-year-old woman presented to the hospital with new-onset PAH and right ventricular dysfunction. Due to the high mortality risk, the patient was initially started on intravenous treprostinil. The clinical course was complicated by probable treprostinil-induced thrombocytopenia. Due to the need for prostacyclin pathway therapy, the decision was made to switch from intravenous treprostinil to oral selexipag. The nadir platelet count was 30,000/μL. Approximately 72 h after discontinuation of treprostinil and maintaining selexipag 1600 mcg twice daily, the platelet count improved to 46,000/μL on the day of discharge. Several days after discharge, the platelet count further improved to 55,000/μL. The repeated platelet count 1 month after discharge normalized to 329,000/μL. Our case report described the successful use of selexipag to overcome treprostinil-induced thrombocytopenia, owing to its limited effect on platelet aggregation.

Authors

Institutions

Publication Details

Journal
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
Published
2026-11-18
DOI
https://doi.org/10.1002/phar.70222
Primary Topic
Pulmonary Hypertension Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Selexipag as a Therapeutic Alternative for Treprostinil‐Induced Thrombocytopenia in Pulmonary Arterial Hypertension: A Case Report

Marco A. Caccamo, Kazuhiko Kido, George G. Sokos, James C. Coons et al.
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
Pulmonary Hypertension Research and Treatments
article

Selexipag as a Therapeutic Alternative for Treprostinil‐Induced Thrombocytopenia in Pulmonary Arterial Hypertension: A Case Report

Marco A. Caccamo, Kazuhiko Kido, George G. Sokos, James C. Coons, Anantha Madgula
article en

Abstract

Parenteral prostacyclin pathway agent-induced thrombocytopenia may require dose reduction or therapy discontinuation to mitigate the adverse events. However, the pulmonary arterial hypertension (PAH) guidelines do not suggest any strategy to overcome treprostinil-induced thrombocytopenia. Selexipag is an oral, non-prostanoid, selective IP receptor agonist. This is the first case report proposing the use of selexipag, due to its minimal thrombocytopenia risk, when severe treprostinil-induced thrombocytopenia occurs in practice. A 66-year-old woman presented to the hospital with new-onset PAH and right ventricular dysfunction. Due to the high mortality risk, the patient was initially started on intravenous treprostinil. The clinical course was complicated by probable treprostinil-induced thrombocytopenia. Due to the need for prostacyclin pathway therapy, the decision was made to switch from intravenous treprostinil to oral selexipag. The nadir platelet count was 30,000/μL. Approximately 72 h after discontinuation of treprostinil and maintaining selexipag 1600 mcg twice daily, the platelet count improved to 46,000/μL on the day of discharge. Several days after discharge, the platelet count further improved to 55,000/μL. The repeated platelet count 1 month after discharge normalized to 329,000/μL. Our case report described the successful use of selexipag to overcome treprostinil-induced thrombocytopenia, owing to its limited effect on platelet aggregation.

Pharmacotherapy The Journal of Human Pharmacology and Drug TherapyVol. 46(12)
West Virginia University (US), University of Pittsburgh (US)
Pulmonary Hypertension Research and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon